• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tessellate BIO Emerges from Stealth

    10/17/23 3:00:00 AM ET
    $NAMS
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NAMS alert in real time by email
    • The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populations
    • Lead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complex
    • Company backed by leading venture firms, BioGeneration Ventures (BGV) and Forbion
    • World-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology

    AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in seed funding backed by two leading European venture capital firms, BioGeneration Ventures (BGV) and Forbion. Its lead program targets the DNA damage response (DDR) and in particular cancers that depend on Alternative Lengthening of Telomeres (ALT).

    The company aims to become a global leader in precision oncology by redefining Synthetic Lethality. While Synthetic Lethality approaches targeting Homology Recombination Deficiency (HRD) have been successfully validated in the clinic by PARP inhibitors, there remains a vast and largely unexplored space in Synthetic Lethality beyond HRD that Tessellate BIO is pioneering.

    Tessellate BIO has attracted an impressive leadership team of seasoned entrepreneurs and industry-experienced drug hunters with proven track records, including: CEO, Andree Blaukat, previously SVP and Head of Oncology Research at Merck KGaA; CSO, Jürgen Moll, previously Head of Molecular Oncology Unit at Sanofi; and serial entrepreneur Andrew Lightfoot, as COO, who initially established the company. In addition, Eliot Forster, most recently former CEO of NASDAQ-listed F-star, has joined as Chair of the Board of Directors.

    Andree Blaukat, CEO, said, "Synthetic Lethality is a proven, but only partly explored concept, and there are large numbers of patients whose needs are not being met by current medicines. I believe applying Synthetic Lethality beyond HRD has the potential to open a new frontier in precision oncology by addressing a wide range of cancer types with highly tumor-targeted treatments."

    Founding investor, board director and Partner at BGV, Daniela Couto, noted, "The know-how and data generated by the scientific founders Prof. Claus Azzalin and Prof. Hilda Pickett around FANCM and ALT got us really excited to kick-start Tessellate BIO. These foundations brought Forbion on board and allowed us to attract an excellent management team. Together, we are creating a very exciting first-in-class pipeline and looking for other like-minded investors to join us."

    Board director and General Partner at Forbion, Rogier Rooswinkel, added, "We are delighted to have joined our partners at BGV and to have built together a company from the ground up. Developing innovative precision oncology drugs requires the right scientific and business leadership, and at Tessellate BIO we have built a world-class team."

    Eliot Forster, Independent Director and Chair of the Board, said, "Novelty in the treatment of cancer is less and less common. Andree and his team are developing a novel approach beyond the already-exploited HRD. This is an enormous opportunity for patients. I have been hugely impressed by the ambition at Tessellate BIO and by the progress already made towards the vision of impacting patient care – turning cancer patients into cancer survivors."

    For further information contact:

    Tessellate BIO

    Andree Blaukat, CEO - [email protected]

    Media Enquiries

    Charles Consultants

    Sue Charles – [email protected] +44 (0)7968 726585

    Chris Gardner - [email protected] +44 (0)7956 031077

    About Tessellate BIO

    Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD.

    The company's strategy is to drive small molecule drug discovery towards novel, validated oncology targets and, critically, the parallel development of associated companion diagnostics, including a potentially best-in-class diagnostic to detect ALT positive cancers for identification of treatment-eligible patients. The company also has follow-on programs in tumor suppressor Loss-of-Function (LoF) settings.

    Led by an experienced team of drug hunters, the company is building a pipeline of first-in-class medicines based on cutting-edge research sourced from international world-renowned laboratories including Children's Medical Research Institute (CMRI), Australia and Instituto de Medicina Molecular (iMM), Portugal. Its lead program targets complexes that are critical for the ALT mechanism including the FANCM protein complex.

    Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion.

    For more information, please visit: www.tessellatebio.com | follow us on LinkedIn

    About Tessellate BIO's lead program - ALT

    ALT is a critical mechanism to maintain the integrity of telomeres, which is essential for the unlimited replicative potential of tumor cells that is a key hallmark of cancer. Many cancers with high unmet medical need and poor prognosis rely on ALT for proliferation. For example, several types of sarcomas have over 60% ALT dependency, and substantial subgroups of many solid tumors are ALT dependent. The lead program targets the FANCM protein complex and is based on the discoveries of Tessellate BIO co-founders Prof. Hilda Pickett (CMRI) and Prof. Claus Azzalin (iMM).

    About BGV

    BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class companies. BGV manages over EUR 400 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.

    For more information, please visit: www.biogenerationventures.com

    About Forbion

    Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages €3 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion's current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with investments in over 95 companies across 10 funds. Forbion's record of sourcing, building and guiding life sciences companies has resulted in many breakthrough therapies and valuable exits. Portfolio company successes include NewAmsterdam Pharma (NASDAQ:NAMS), Gyroscope (acquired by Novartis) and Replimune (NASDAQ:REPL). Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

    For more information, please visit: www.forbion.com



    Primary Logo

    Get the next $NAMS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NAMS
    $REPL

    CompanyDatePrice TargetRatingAnalyst
    Replimune Group Inc.
    $REPL
    7/23/2025$2.00Outperform → Underperform
    BMO Capital Markets
    Replimune Group Inc.
    $REPL
    7/23/2025Buy → Neutral
    H.C. Wainwright
    Replimune Group Inc.
    $REPL
    7/23/2025$3.00Overweight → Equal Weight
    Barclays
    Replimune Group Inc.
    $REPL
    7/22/2025$3.00Outperform → Market Perform
    Leerink Partners
    Replimune Group Inc.
    $REPL
    7/22/2025$9.00Overweight → Neutral
    Analyst
    Replimune Group Inc.
    $REPL
    7/22/2025$4.00Outperform → Neutral
    Wedbush
    Replimune Group Inc.
    $REPL
    7/22/2025$3.00Overweight → Neutral
    Piper Sandler
    NewAmsterdam Pharma Company N.V.
    $NAMS
    7/17/2025$27.00Neutral
    Goldman
    More analyst ratings

    $NAMS
    $REPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Kling Douglas F exercised 98,612 units of Ordinary Shares at a strike of $10.90 and sold $2,096,655 worth of Ordinary Shares (98,612 units at $21.26) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      7/17/25 5:19:01 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $69,466 worth of Ordinary Shares (3,780 units at $18.38) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      6/26/25 7:41:52 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Kling Douglas F exercised 100,000 units of Ordinary Shares at a strike of $10.20 and sold $1,929,141 worth of Ordinary Shares (100,000 units at $19.29) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      6/18/25 4:50:44 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NAMS
    $REPL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $69,466 worth of Ordinary Shares (3,780 units at $18.38) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      6/26/25 7:41:52 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $167,381 worth of Ordinary Shares (8,584 units at $19.50) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      6/18/25 4:42:40 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $25,521 worth of Ordinary Shares (1,135 units at $22.49) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      3/28/25 5:36:48 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NAMS
    $REPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Replimune downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Replimune from Outperform to Underperform and set a new price target of $2.00

      7/23/25 7:43:21 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Replimune from Buy to Neutral

      7/23/25 7:42:18 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune downgraded by Barclays with a new price target

      Barclays downgraded Replimune from Overweight to Equal Weight and set a new price target of $3.00

      7/23/25 7:42:18 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NAMS
    $REPL
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Replimune Group Inc.

      DEFA14A - Replimune Group, Inc. (0001737953) (Filer)

      7/25/25 4:18:29 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Replimune Group Inc.

      DEF 14A - Replimune Group, Inc. (0001737953) (Filer)

      7/25/25 4:16:04 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Replimune Group, Inc. (0001737953) (Filer)

      7/22/25 8:18:47 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NAMS
    $REPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

      WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The CRL indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial eviden

      7/22/25 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 16 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 32,135 shares of the Company's common stock and restricted stock units representing an aggregate of 64,320 s

      7/11/25 4:01:00 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 10 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 36,485 shares of the Company's common stock and restricted stock units representing an aggregate of 41,080 s

      6/6/25 4:01:00 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NAMS
    $REPL
    Leadership Updates

    Live Leadership Updates

    See more
    • Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

      Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

      5/8/25 5:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

      NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

      4/17/25 4:01:00 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $NAMS
    $REPL
    Financials

    Live finance-specific insights

    See more
    • Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

      WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025. Fiscal Fourth Quarter Earnings Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the

      5/16/25 8:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

      Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat

      6/6/24 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

      RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s

      12/5/23 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NAMS
    $REPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

      SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      12/17/24 5:35:24 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

      SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      12/17/24 4:00:47 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

      SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

      12/17/24 10:28:58 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care